Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer
      loading

      Chapter

      Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer

      DOI link for Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer

      Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer book

      Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer

      DOI link for Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer

      Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer book

      ByRoberta Ferraldeschi, Gerhardt Attard
      BookHandbook of Metastatic Breast Cancer

      Click here to navigate to parent product.

      Edition 2nd Edition
      First Published 2012
      Imprint CRC Press
      Pages 17
      eBook ISBN 9780429108853
      Share
      Share

      ABSTRACT

      INTRODUCTION Breast cancer is a heterogeneous disease that encompasses several distinct entities with different biological characteristics and clinical behaviors. Currently, treatment decisions for metastatic breast cancer patients are made based on a small number of well-established molecular biomarkers, including the oestrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth receptor 2 (HER2), as well as clinicopathological features. The biological importance of these established biomarkers has been reinforced over the last decade with the identifi cation of discrete genetic subtypes of breast cancer with distinct prognoses (section “Established Biomarkers” and chap 4) ( 1 , 2 ). Advances in high throughput technologies including proteomics, expression array technologies, copy number measurements, and most recently next generation sequencing, will signifi cantly increase the potential to identify a variety of biomarkers and assign single tumours to specifi c molecular subgroups, even when small amounts of tumour tissue are available ( 3 ). Furthermore, the study of circulating biomarkers (section “Circulating Biomarkers”) offers the promise of analysing tumours comprehensively at the molecular level in “real-time” without subjecting patients to multiple clinical interventions to obtain tissue. This chapter will focus on recent advances in biomarker research, especially the use of circulating biomarkers, and will give some examples as to how these could impact the management of breast cancer patients.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited